Skip to content
FoodEdge
News

Applied Nutrition: EUR 193.6M (GBP 161.6M) sales, GLP-1 share undisclosed

Revenue up 50.9%, margins down, cash from operations down 15.1%. What the RNS, a broker and whey price data say about GLP-1 demand and whey costs.

For Startups
AI-generated illustration of plain unlabelled white protein powder tubs on a pallet beside paper sacks of whey powder in a warehouse.
Illustration: AI-generated for FoodEdge.

Applied Nutrition plc (LSE: APN), a UK sports nutrition brand, grew revenue 50.9% to €193.6M (GBP 161.6M) in the year to 31 July 2026, according to its unaudited preliminary results (RNS 2802D, 16 November 2026). Adjusted EBITDA rose 40.1% to €51.9M (GBP 43.3M). The shares fell 3.65% on the day, Sharecast reported, after the company kept its FY27 guidance unchanged.

GLP-1 features prominently. The company cites IGD research showing GLP-1 use among UK consumers rising from 3.1% in June 2025 to 6% in March 2026, launched a GLP-1 Friendly Range and signed an out-licensing deal with Morrisons for high-protein foods aimed partly at GLP-1 users. The announcement gives no revenue for either. The growth it does break down came from every region: UK sales up 45.2%, with grocers up 180%; Europe up 34.0%; Rest of World up 63.3%, helped by a Middle East recovery and Latin America up more than 190%. Critical Whey, relaunched in FY26, grew 142%. The results show strong protein demand without showing how much of it comes from GLP-1 users.

Margins are moving the other way. Gross margin fell 190 basis points to 44.1%, which the company puts mainly down to staff costs and off-site storage. Adjusted EBITDA margin fell from 28.9% to 26.8% (FoodEdge calculation). FY27 guidance is about €245.7M (GBP 205M) revenue and €58.7M (GBP 49M) adjusted EBITDA, a margin near 23.9%. The company calls this a slight decrease and cites lower-margin US white-label sales, "significantly higher whey protein costs" and a larger share of whey-based products, partly offset by price rises.

Whey is the swing factor. Independent price reporter DCA Market Intelligence set a record WPC80 benchmark of €26,450 a tonne in late May 2026, citing GLP-1 demand. By November its benchmark was still falling, and Vesper reported European WPC80 level with milk protein concentrate. Broker Peel Hunt raised its FY27 forecasts above guidance, to about €261.2M (GBP 218M) revenue and €63.5M (GBP 53M) EBITDA, citing falling whey prices, Proactive reported; it kept a hold rating. The company itself expects whey to cost more on average in FY27 than in FY26.

Cash is the other pressure. Net cash from operations fell 15.1% to €22.3M (GBP 18.6M) as working capital rose 68.0%, mostly stock, and year-end net cash was €19.1M (GBP 15.9M). The company does not expect to pay a dividend before FY28. In June it bought the trade and most assets of US maker Nutrablend for about €14.4M (GBP 12M), with capacity for about €272.4M (US$300M) of revenue a year.

What to check

  • What revenue do the GLP-1 Friendly Range and the Morrisons licence bring in, and at what margin?
  • Guidance and broker forecasts read the same whey market differently. Which whey price is in the FY27 budget?
  • How much of the 68% working capital increase is whey bought near the price peak?

Sources and reporting

  1. Applied Nutrition plc: Preliminary results for the year ended 31 July 2026, RNS 2802D, 16 November 2026 (primary)
  2. Proactive: Applied Nutrition falls 7% despite Peel Hunt upgrades, 16 November 2026 (secondary, broker note)
  3. Sharecast: London midday market report, 16 November 2026 (secondary)
  4. Stockopedia: Applied Nutrition share price down 4%, 16 November 2026 (secondary, analysis)
  5. DCA Market Intelligence: WPC80 prices reach new record, 28 May 2026, and WPC80 drops to under the level of MPC85, 11 November 2026 (independent price reporting agency)
  6. Vesper: WPC80 falls level with MPC85, 5 November 2026 (independent market analysis)

Reporting note: Company figures come from RNS 2802D, read in full on 17 November 2026, and match independent coverage by Proactive, Sharecast and Stockopedia. Intraday share falls were reported at between 3.65% and 7%; this article uses Sharecast's midday figure. The EBITDA margins of 28.9%, 26.8% and about 23.9% are FoodEdge calculations from reported figures and guidance. Peel Hunt's forecasts are as reported by Proactive; FoodEdge has not seen the note. The current WPC80 benchmark level sits behind DCA's paywall and is not quoted. Currency: ECB euro reference rates of 16 November 2026, €1 = GBP 0.83450 and €1 = US$1.1014. FoodEdge has not spoken to Applied Nutrition.

AI tools supported source research and drafting during the editorial process.

DiscussionOpenClose

More to explore

All publications